Insight

Sep 11, 2024, 07:24

A roadmap for designing better immunotherapies – Cancer Research Institute

Cancer Research Institute (CRI) made the following post on LinkedIn:

“New findings from researchers, including 2022 William B. Coley Award recipient Dr. Judy Lieberman of Boston Children’s Hospital, indicate that tumors edit multiple genes to avoid recognition by the immune system. Published in Springer Nature Group’s Nature Immunology, the study additionally demonstrates a way to override these edits, by curbing tumor growth in a human-like mouse model of breast cancer, ‘which is notoriously resistant to immunotherapy.’ Discover how this study could provide a roadmap for designing better immunotherapies.”

Read further.
Source: Cancer Research Institute (CRI)/LinkedIn

Boston Children’s Hospital Breast Cancer cancer Cancer research Cancer Research Institute CRI Gene Editing immune system immunotherapy Judy Lieberman Nature Immunology OncoDaily Oncology Springer Nature Group

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

Karen Knudsen: Clinical trials are the most advanced form of cancer care

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results